Company Filing History:
1 out of 2,405 
1 out of 55 Years Active: 2019
Title: William De Wildt – Innovator in CCR5 Antagonism
Introduction
William De Wildt is an accomplished inventor based in Wijchen, Netherlands. With a keen interest in pharmaceutical innovations, he has made significant contributions to the field, particularly in the development of compounds that inhibit the CCR5 receptor.
Latest Patents
William De Wildt holds one patent, which details the crystalline forms of a CCR5 antagonist. This patent, titled "Crystal forms of a CCR5 antagonist," relates to forms of a CCR5 inhibitory compound characterized by the chemical structure (4,6-dimethylpyrimidin-5-yl)(4-((3S)-4-((1R)-2-methoxy-1-(4-(trifluoromethyl)phenyl)ethyl)-3-methyl-piperazin-1-yl)-4-methylpiperidin-1-yl)methanone.
Career Highlights
Throughout his career, De Wildt has been associated with prestigious organizations, including Merck Sharp & Dohme Corporation and Merck Sharp & Dohme B.V. His work in these companies has primarily focused on advancing pharmaceutical research and development, showcasing his expertise in the industry.
Collaborations
In his innovative journey, William has collaborated with notable professionals, including Alfred Lee. These partnerships have enriched his research experience and contributed to his success in creating groundbreaking pharmaceutical compounds.
Conclusion
William De Wildt is a testament to the impact of innovation in the pharmaceutical sector. His singular patent highlights not only his inventive spirit but also his commitment to advancing healthcare solutions through scientific research. As his career continues, it will be exciting to see how his contributions further shape the landscape of drug development.